Condensed Consolidated Statements of Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Condensed Consolidated Statements of Loss
Revenue	$ 0	$ 0	$ 0	$ 1,000
Operating expenses
Research and development, net of tax credits	3,963	6,721	10,417	25,600
General and administrative	3,742	4,227	12,741	12,561
Commercial	1,911	4,412	6,596	10,137
Loss from operations	(9,616)	(15,360)	(29,754)	(47,298)
Interest income	1,080	1,120	3,260	2,921
Interest expense	(903)	(841)	(2,662)	(1,697)
Net loss and comprehensive loss	$ (9,439)	$ (15,081)	$ (29,156)	$ (46,074)
Weighted average number of shares and pre-funded warrants outstanding, basic (in shares)	66,190,302	42,973,160	60,856,495	42,920,620
Weighted average number of shares and pre-funded warrants outstanding, diluted (in shares)	66,190,302	42,973,160	60,856,495	42,920,620
Net loss per share, basic (in dollars per share)	$ (0.14)	$ (0.35)	$ (0.48)	$ (1.07)
Net loss per share, diluted (in dollars per share)	$ (0.14)	$ (0.35)	$ (0.48)	$ (1.07)